Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Zelira Therapeutics ( (AU:ZLD) ) just unveiled an announcement.
Zelira Therapeutics has announced significant progress in its diabetic neuropathy study, with its proprietary cannabinoid-based therapy, ZLT-L-007, outperforming Lyrica® in reducing pain and improving quality of life for patients. This advancement, alongside the conversion of US$3.25 million in convertible notes into equity, strengthens Zelira’s financial position and supports its clinical and regulatory development efforts. The company is poised to continue its momentum with upcoming FDA trials and the optimization of its Zyraydi™ technology, aiming to unlock value across its product lines.
More about Zelira Therapeutics
Zelira Therapeutics Ltd is a global leader in the development and commercialization of clinically validated cannabinoid-based medicines. The company focuses on creating therapies that address various medical conditions, leveraging its expertise in cannabinoid science to offer innovative solutions across multiple therapeutic verticals and geographies.
Average Trading Volume: 4,920
Technical Sentiment Signal: Sell
Current Market Cap: A$4.88M
See more insights into ZLD stock on TipRanks’ Stock Analysis page.